AGMB
NASDAQAgomAb Therapeutics NV
$11.11+0.61 (+5.81%)
News25/Ratings3
Price$11.11-4.10 (-26.96%)
2026-02-062026-04-24
News · 26 weeks25-69%
2025-11-022026-04-26
Mix2590d
- Insider11(44%)
- Other5(20%)
- SEC Filings4(16%)
- Analyst3(12%)
- Offering2(8%)
Latest news
25 items- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 ---- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Hal
- SECSEC Form 20-F filed by AgomAb Therapeutics NV20-F - Agomab Therapeutics NV (0002020932) (Filer)
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- PRAgomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary FibrosisAntwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions. "The issuance of th
- INSIDERSEC Form 3 filed by new insider Bond Colin Michael3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Van Der Horst Paul Henryk3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Knotnerus Tim Jasper3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Borderias Andrea Saez3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Verduyn-Van Weegen Felice Isabel3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Epstein David R3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lefever Ellen3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hammer Ohad3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kemula Pierre Thadee Victor3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wiesel Philippe Constantin3 - Agomab Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jahreis Angelika Martha3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SECSEC Form S-8 filed by AgomAb Therapeutics NVS-8 - Agomab Therapeutics NV (0002020932) (Filer)
- SECSEC Form SCHEDULE 13G filed by AgomAb Therapeutics NVSCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- ANALYSTMorgan Stanley initiated coverage on AgomAb Therapeutics NV with a new price targetMorgan Stanley initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $28.00
- ANALYSTAnalyst initiated coverage on AgomAb Therapeutics NV with a new price targetAnalyst initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $32.00
- ANALYSTLeerink Partners initiated coverage on AgomAb Therapeutics NV with a new price targetLeerink Partners initiated coverage of AgomAb Therapeutics NV with a rating of Outperform and set a new price target of $36.00
- SECSEC Form SCHEDULE 13D filed by AgomAb Therapeutics NVSCHEDULE 13D - Agomab Therapeutics NV (0002020932) (Subject)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Announces Closing of Initial Public OfferingANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares ("ADSs") representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The aggregate gross proceeds to Agomab from the offering were approximately $200.0 million, before deducting underwriting discounts and commissions an